5-戊基-1,2-恶唑-3-羧酸 | 89967-39-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-戊基-1,2-恶唑-3-羧酸
• 英文名称: 5-pentylisoxazole-3-carboxylic acid
• 英文别名: 5-Pentyl-1,2-oxazole-3-carboxylic acid
• CAS: 89967-39-5
• 化学式: C₉H₁₃NO₃
• 分子量: 183.207
• InChiKey: WCZXKMNWORSJGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-四氢呋喃基甲胺盐酸盐 、 5-戊基-1,2-恶唑-3-羧酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 氯仿 为溶剂， 以0.1 g的产率得到N-((tetrahydrofuran-3-yl)methyl)-5-pentylisoxazole-3-carboxamide
  参考文献：
  名称：

  Amide compound, an arthropod pest control agent and a method for controlling arthropod pest

  摘要：

  公开号：

  EP2952096B1
• 作为产物：
  描述：

  5-戊基-1,2-恶唑-3-羧酸乙酯 在 sodium hydroxide 作用下， 生成 5-戊基-1,2-恶唑-3-羧酸
  参考文献：
  名称：

  Syntheses of heteroaromatic carboxylic acids closely related to fusaric acid.

  摘要：

  为了研究在fusari酸（5-丁基-2-吡啶酸）及其衍生物代谢中观察到的链延长反应的普遍性，合成了多种具有正常烷基侧链的杂芳香羧酸（嗪类、1,3-噁唑类和1,2-噁唑类）。

  DOI：

  10.1248/cpb.31.4549

文献信息

• Novel therapeutic compounds
  申请人：Breinlinger Eric C.

  公开号：US20090069288A1

  公开（公告）日：2009-03-12

  Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.

  本文公开了公式（I）的新化合物，其中变量如本文所定义。公式（I）的化合物可用作激酶抑制剂，因此可用于治疗某些疾病和病症，特别是炎症性疾病和疾病以及增生性疾病，如癌症。
• METHOD FOR CONTROLLING ARTHROPOD PEST
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20150344466A1

  公开（公告）日：2015-12-03

  An amide compound represented by formula (I): [wherein A represents a 3- to 7-membered saturated heterocyclic ring which contains, as ring-forming component(s), one or more atoms or groups selected from the group consisting of an oxygen atom and —S(O) t —, t represents 0, etc., R 1 and R 2 are the same or different and represent a hydrogen atom, etc., n represents 0, etc., the following formula (II): represents a 5-membered aromatic ring, in which Z represents a nitrogen atom or a carbon atom and X 1 , X 2 and X 3 are the same or different and represent a nitrogen atom, etc., R 3 and R 4 are the same or different and represent a hydrogen atom, etc., m represents 0 to 2, Q represents one group selected from group A or a C1 to C8 chain hydrocarbon group optionally having one group selected from group A, Y represents an oxygen atom, etc., u represents 0, etc., and v represents 0, etc.] has excellent arthropod pest controlling effects.

  化合物式(I)所代表的酰胺化合物：[其中A代表一个3到7个成员的饱和杂环环，该环包含作为环构成组分之一或多个原子或基团，所选自氧原子和—S（O）t—群，t代表0等；R1和R2相同或不同，代表氢原子等；n代表0等；下列式子(II)代表一个5个成员的芳香环，在该环中Z代表一个氮原子或一个碳原子，X1、X2和X3相同或不同，代表氮原子等，R3和R4相同或不同，代表氢原子等，m代表0到2，Q代表从群A中选择的一个群或一个C1到C8链烃基团，该基团可以选择从群A中选择的一个群，Y代表氧原子等，u代表0等，v代表0等]具有优良的节肢动物害虫控制效果。
• Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases
  作者：Philip A. Harris、Scott B. Berger、Jae U. Jeong、Rakesh Nagilla、Deepak Bandyopadhyay、Nino Campobasso、Carol A. Capriotti、Julie A. Cox、Lauren Dare、Xiaoyang Dong、Patrick M. Eidam、Joshua N. Finger、Sandra J. Hoffman、James Kang、Viera Kasparcova、Bryan W. King、Ruth Lehr、Yunfeng Lan、Lara K. Leister、John D. Lich、Thomas T. MacDonald、Nathan A. Miller、Michael T. Ouellette、Christina S. Pao、Attiq Rahman、Michael A. Reilly、Alan R. Rendina、Elizabeth J. Rivera、Michelle C. Schaeffer、Clark A. Sehon、Robert R. Singhaus、Helen H. Sun、Barbara A. Swift、Rachel D. Totoritis、Anna Vossenkämper、Paris Ward、David D. Wisnoski、Daohua Zhang、Robert W. Marquis、Peter J. Gough、John Bertin

  DOI：10.1021/acs.jmedchem.6b01751

  日期：2017.2.23

  RIP1 regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP1 kinase that are suitable for advancement into the clinic have yet to be described. Herein, we report our lead optimization of a benzoxazepinone hit from a DNA-encoded library and the discovery and profile of clinical candidate GSK2982772 (compound 5), currently in phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. Compound 5 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. Highlighting, its potential as a novel anti-inflammatory agent, the inhibitor was also able to reduce spontaneous production of cytokines from human ulcerative colitis explants. The highly favorable physicochemical and ADMET properties of 5, combined with high potency, led to a predicted low oral dose in humans.
• JP2015/51963
  申请人：——

  公开号：——

  公开（公告）日：——
• YAMANAKA, HIROSHI;MIZUGAKI, MICHINAO;SAKAMOTO, TAKAO;SAGI, MATAICHI;NAKAG+, CHEM. AND PHARM. BULL., 1983, 31, N 12, 4549-4553
  作者：YAMANAKA, HIROSHI、MIZUGAKI, MICHINAO、SAKAMOTO, TAKAO、SAGI, MATAICHI、NAKAG+

  DOI：——

  日期：——